Histopathological Study of Cervical Lesions in a Tertiary Healthcare Center in India
Authors/Creators
- 1. Tutor, Department of Pathology, Patna Medical College and Hospital, Patna, Bihar, India
- 2. Professor, Department of Pathology, Patna Medical College and Hospital, Patna, Bihar, India
- 3. Professor and HOD, Department of Pathology, Patna Medical College and Hospital, Patna, Bihar, India
Description
This retrospective study aimed to analyze the histopathological characteristics of cervical lesions in 85 female patients at Patna Medical College and Hospital, Patna, between March 2018 and October 2019. The histopathological examination revealed that 56.5% of the lesions were benign, 25.9% were pre-malignant, and 17.6% were malignant, with squamous cell carcinoma being the predominant malignant type. The highest prevalence of pre-malignant and malignant lesions was observed in the 30-50-year age group. These findings underscore the importance of regular cervical screening and histopathological evaluation for early detection and management of cervical lesions, thereby preventing the progression to invasive cancer. The study provides valuable insights for improving cervical health programs and clinical practices in India.
Abstract (English)
This retrospective study aimed to analyze the histopathological characteristics of cervical lesions in 85 female patients at Patna Medical College and Hospital, Patna, between March 2018 and October 2019. The histopathological examination revealed that 56.5% of the lesions were benign, 25.9% were pre-malignant, and 17.6% were malignant, with squamous cell carcinoma being the predominant malignant type. The highest prevalence of pre-malignant and malignant lesions was observed in the 30-50-year age group. These findings underscore the importance of regular cervical screening and histopathological evaluation for early detection and management of cervical lesions, thereby preventing the progression to invasive cancer. The study provides valuable insights for improving cervical health programs and clinical practices in India.
Files
IJPCR,Vol16,Issue5,Article430.pdf
Files
(2.0 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:079592879932b33e9b161b90d42b9e75
|
2.0 MB | Preview Download |
Additional details
Dates
- Accepted
-
2024-05-15
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue5,Article430.pdf
- Development Status
- Active
References
- 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. 2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394- 424. 3. Denny L. Cervical cancer prevention: new opportunities for primary and secondary prevention in the 21st century. Int J Gynecol Obstet. 2012;119(Suppl 1):S80-4. 4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9. 5. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385-94. 6. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med. 2003;348(6):489-90. 7. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244-65. 8. WHO. Comprehensive cervical cancer control: a guide to essential practice. 2nd ed. Geneva: World Health Organization; 2014. 9. Gaffikin L, Blumenthal PD, Emerson M, Limpaphayom KK. Safety, acceptability, and feasibility of a single-visit approach to cervicalcancer prevention in rural Thailand: a demon-stration project. Lancet. 2003;361(9360):814- 20. 10. Denny L, Kuhn L, Pollack A, Wright TC Jr. Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer. 2002;94(6):1699- 707. 11. Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards-Kortum R. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;91(4):626-31. 12. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007; 90:1-636. 13. Lax SF. Histopathology of cervical precursor lesions and cancer. Acta Dermatovenerol Alp Pannonica Adriat. 2011;20(3):125-33. 14. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114- 9. 15. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol. 20 10;11(11):1048-56. 16. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342-50. 17. Sankaranarayanan R, Rajkumar R, Esmy PO, Fayette JM, Shanthakumari S, Frappart L, et al. Effectiveness, safety and acceptability of visual inspection with acetic acid (VIA) and Lugol's iodine (VILI) in cervical cancer screening in rural India. Int J Cancer. 2004; 119(3):519-25. 18. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89 (1): 101-5. 19. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ. 2001;164(7):1017-25. 20. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European guidelines for quality assurance in cervical cancer screening. 2nd ed. Luxembourg: Office for Official Publications of the European Communities; 2008.